NEW YORK CITY, NY / ACCESS Newswire / October 22, 2025 / Attorney Advertising Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organogenesis Holdings Inc. ("Organogenesis" or "the Company") (NASDAQ:ORGO). Investors who purchased Organogenesis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ORGO.

Investigation Details

On September 25, 2025, Organogenesis issued a press release disclosing that the second Phase 3 trial of ReNu failed to meet its primary endpoint. According to the Company, the trial did not demonstrate a statistically significant change in pain reduction. Following this news, shares of Organogenesis fell by almost 12.4% on the next day.

What's Next?

If you are aware of any facts relating to this investigation or purchased Organogenesis securities, you can assist this investigation by visiting the firm's site: bgandg.com/ORGO. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire